Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 11/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104778 | 1.00 | RBP4 (0.56) | RBP4PTPN1SRD5A2PLA2G1BATG4B | |
| SCHEMBL3104734 | 0.89 | RBP4 (0.53) | RBP4 | |
| SCHEMBL3104738 | 0.89 | RBP4 (0.53) | RBP4 | |
| SCHEMBL13034467 | 0.87 | RBP4 (0.52) | RBP4PTPN1 | |
| SCHEMBL3107777 | 0.87 | RBP4 (0.58) | RBP4PLA2G1BATG4B | |
| SCHEMBL3094503 | 0.86 | RBP4 (0.69) | RBP4PLA2G1BATG4B | |
| SCHEMBL3108139 | 0.85 | RBP4 (0.65) | RBP4PLA2G1BATG4B | |
| SCHEMBL3100376 | 0.83 | RBP4 (0.61) | RBP4PLA2G1BATG4B | |
| SCHEMBL18404361 | 0.83 | RBP4 (0.61) | RBP4PLA2G1BATG4B | |
| SCHEMBL13299697 | 0.82 | RBP4 (0.60) | RBP4PLA2G1BATG4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202223-B1 | HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-9487509-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-8586571-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2202223-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | RBP4 1/4885PTPN1 1967/4885SRD5A2 904/4885 |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | RBP4 1/4885PTPN1 1967/4885SRD5A2 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.